Renal cell cancer after kidney transplantation

Abstract

Longer pre-transplant dialysis, cyclosporine-based protocols and/or intensified immunosuppression with additional mycophenolate mofetil, and larger proportions of time of prednisolone treatment during follow-up increase de novo RCC risk.

Development of Bilateral Renal Cell Carcinoma in the Birt-Hogg-Dubé Syndrome Before and After Living-Related Kidney Transplantation

“…11,12 However, we performed a radical nephrectomy in the present case because our patient (diagnosed with BHD syndrome) was a transplant recipient; these patients are generally at an increased risk of developing malignancies following immunosuppressive therapy. 13,14 Our patient developed left and right renal cancer before and after kidney transplantation, respectively. Pathological findings revealed that both the left and right RCCs were HOCTs.…”

“…However, we performed a radical nephrectomy in the present case because our patient (diagnosed with BHD syndrome) was a transplant recipient; these patients are generally at an increased risk of developing malignancies following immunosuppressive therapy. 13 , 14 …”

Double partial nephrectomy in allograft transplanted kidney

“…A recent study from Germany examined 1655 transplant patients for approximately 12 years. 3 Twenty-six cases of RCC after transplantation were diagnosed. Post-transplant RCC was significantly associated with longer durations of pre-transplant haemodialysis (p = 0.007), post-transplant immunosuppression with cyclosporine (p = 0.029) and/or mycophenolate (p = 0.020) and with post-transplant prednisolone (p = 0.042).…”

Urological Cancers and Kidney Transplantation: a Literature Review

“…Reducing or modifying immunosuppressive therapy may contribute to reduce the incidence of RCC [100] as well as slowing tumor progression, without compromising graft function [3,101]. Kleine-Döpke and colleagues demonstrated an increased risk in RCC incidence among patients using CYA and MMF (HR 2.8, 95% CI 1.009-9.97; HR 5.39, 95% CI 1.54-18.83, respectively) [102]. Hope and colleagues reported 87 RTRs with de novo cancer diagnosis, in which 36 patients had dose reduction or interruptions of AZT, CYA, and tacrolimus; of note, they reported no impairment of graft function, although no change in cancer free survival was documented in solid organ cancers [103].…”